目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T79469 | HBV | ||
HBV-IN-34(化合物17i)是一款抗HBV药物,可以有效抑制HBsAg的生成。在体外实验中,HBV-IN-34对HBVDNA和HBsAg的EC50值分别为0.018 μM和0.044 μM,显示出卓越的抗病毒活性。 | |||
T78812 | HBV | ||
HBV-IN-36(compound 42)是一种抗乙型肝炎病毒(HBV)活性显著的化合物,其抑制剂效力(IC50=2 μM)以及EC50值为0.85 μM,表明其作为HBV抑制剂具有潜在的临床应用价值。 | |||
T73283 | |||
HBV-IN-31 是一种有效的共价闭合环状 DNA (cccDNA) 抑制剂。HBV-IN-31 具有抗HBV 活性,对 HBsAg 的 IC50值为 0.14 µM。HBV-IN-31 抑制细胞生长。 | |||
T61115 | |||
HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA>452 μg/mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1]. | |||
T62144 | |||
HBV-IN-12 是一种乙型肝炎表面抗原 (HBsAg) 的有效抑制剂。 | |||
T62434 | |||
HBV-IN-10 是一种 compound 6 (WO2021204258A1) 的异构体。其中 Compound 6 是一种乙型肝炎表面抗原 (HBsAg) 的有效抑制剂 (0.1 μM< EC50≤1 μM)。 | |||
T15573 | HCV Protease | ||
Inarigivir soproxil (SB9200) 是一种先天免疫激动剂。 它还显示出针对耐药丙型肝炎病毒 (HCV) 变体的有效抗病毒活性。在基因型 1 HCV 复制子系统细胞中, HCV 1a/1b 的 EC50 为 2.2 和 1.0 μM。 | |||
T9518 | HBV | ||
Inarigivir ammonium (SB-9200 ammonium) 是一种二核苷酸抗病毒化合物,可显着降低表达乙型肝炎病毒的转基因小鼠的 HBV DNA。它是一种激活细胞内先天免疫的视黄酸诱导基因-I 激动剂。 | |||
T6846 | Apoptosis HCV Protease HBV TLR HIV Protease | ||
Vesatolimod (GS-9620) 是一种选择性 Toll 样受体 7 口服激动剂,EC50值为291 nM。 | |||
T63937 | |||
HBV-IN19 TFA 能够抑制 HBsAg 分泌和/或产生,并对乙型肝炎病毒 (HBV) 感染具有抑制作用,能够用于 HBV 感染 (包括慢性 HBV 感染) 的研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01492 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01501 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01491 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPY-05822 | Hepatitis B Virus (HBV)(ayw/France/Tiollais/1979) Capsid protein (His) | HBV-D | E. coli | ||
Hepatitis B virus (HBV) capsid assembly is a critical step in the propagation of the virus and is mediated by the core protein. The first cytoplasmic step in the formation of an infectious HBV virion is the formation of a capsid containing pregenomic RNA (pgRNA) and the viral polymerase (Pol). HBV capsid assembly is an attractive target for new antiviral therapies.
|
|||||
TMPH-00803 | HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25.4 kDa and the accession number is P03148.
|
|||||
TMPH-00807 | HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.6 kDa and the accession number is P03165.
|
|||||
TMPH-00806 | HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.7 kDa and the accession number is O93195.
|
|||||
TMPH-00816 | HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 45.1 kDa and the accession number is P03141.
|
|||||
TMPH-00808 | HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 22.6 kDa and the accession number is Q9QMI3.
|
|||||
TMPH-00815 | HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) | HBV-A | E. coli | ||
HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 28.9 kDa and the accession number is P0C693.
|
|||||
TMPH-00804 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) | HBV-C | P. pastoris (Yeast) | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 23.0 kDa and the accession number is P0C6H7.
|
|||||
TMPH-00805 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) | HBV-C | E. coli | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 27.1 kDa and the accession number is P0C6H7.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|
|||||
TMPY-04567 | SRPK1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells | ||
Serine / threonine-protein kinase SRPK1, also known as SFRS protein kinase 1, Serine/arginine-rich protein-specific kinase 1, SR-protein-specific kinase 1 and SRPK1, is a cytoplasm and nucleus protein that belongs to the protein kinase superfamily and CMGC Ser/Thr protein kinase family. Isoform 2 of SRPK1 is predominantly expressed in the testis but is also present at lower levels in heart, ovary, small intestine, liver, kidney, pancreas and skeletal muscle. Isoform 1 of SRPK1 is only seen in the testis, at lower levels than isoform 2. SRPK1 hyperphosphorylates RS domain-containing proteins such as SFRS1, SFRS2 and ZRSR2 on serine residues during metaphase but at lower levels during interphase. SRPK1 plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. SRPK1 locks onto SFRS1 to form a stable complex and processively phosphorylates the RS domain. SRPK1 appears to mediate HBV core protein phosphorylation which is a prerequisite for pregenomic RNA encapsidation into viral capsids.
|